Dynamic neurocognitive adaptation in aging: Development and validation of a new scale.

IF 4.9 Q1 CLINICAL NEUROLOGY Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-01-20 eCollection Date: 2025-01-01 DOI:10.1002/trc2.70049

Filippo Cieri, Giulia Di Francesco, Chad Lee Cross, Andrew Bender, Jessica Zoe Kirkland Caldwell

{"title":"Dynamic neurocognitive adaptation in aging: Development and validation of a new scale.","authors":"Filippo Cieri, Giulia Di Francesco, Chad Lee Cross, Andrew Bender, Jessica Zoe Kirkland Caldwell","doi":"10.1002/trc2.70049","DOIUrl":null,"url":null,"abstract":"Introduction: Forty-five percent of Alzheimer's disease (AD) cases may have been preventable through protective factors. Reserve, resilience, and resistance share common neurocognitive adaptive processes, acting through protective mechanisms. In this article we propose the development and validation of a new scale, called dynamic Neurocognitive Adaptation, developed in this direction.Methods: We included 815 participants (50% women; 65+ years inclusive of age), divided into two subsamples for exploratory and confirmatory factor analysis. Our initial scale was composed of 30 items, investigating seven dimensions, explored by a 5-point Likert scale reflecting the frequency of activities, for seven time windows.Results: Our final scale had 20 items divided among four dimensions: physical, cognitive, creative, and social. There were no issues related to multi-collinearity or non-collinearity. Kaiser-Meyer-Olkin (KMO) = 0.80 and Bartlett's test of sphericity indicated all values ≤0.01; Cronbach's alpha = 0.83.Discussion: We have validated a reliable, novel, easy to complete, and comprehensive scale to assess lifetime behaviors, which can be applied in research on AD risk reduction, mild cognitive impairment, and in clinical practice.Highlights: Reserve, resistance, and resilience share similar adaptive mechanisms.Dynamic Neurocognitive Adaptation is a new scale to assess lifetime protective factors.Dynamic Neurocognitive Adaptation is a reliable, novel, and easy to complete scale.This approach can characterize specific life stages that are ripe for risk-reduction interventions.Our scale can be used to personalize health recommendations in aging.","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 1","pages":"e70049"},"PeriodicalIF":4.9000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11746070/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/trc2.70049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Forty-five percent of Alzheimer's disease (AD) cases may have been preventable through protective factors. Reserve, resilience, and resistance share common neurocognitive adaptive processes, acting through protective mechanisms. In this article we propose the development and validation of a new scale, called dynamic Neurocognitive Adaptation, developed in this direction.

Methods: We included 815 participants (50% women; 65+ years inclusive of age), divided into two subsamples for exploratory and confirmatory factor analysis. Our initial scale was composed of 30 items, investigating seven dimensions, explored by a 5-point Likert scale reflecting the frequency of activities, for seven time windows.

Results: Our final scale had 20 items divided among four dimensions: physical, cognitive, creative, and social. There were no issues related to multi-collinearity or non-collinearity. Kaiser-Meyer-Olkin (KMO) = 0.80 and Bartlett's test of sphericity indicated all values ≤0.01; Cronbach's alpha = 0.83.

Discussion: We have validated a reliable, novel, easy to complete, and comprehensive scale to assess lifetime behaviors, which can be applied in research on AD risk reduction, mild cognitive impairment, and in clinical practice.

Highlights: Reserve, resistance, and resilience share similar adaptive mechanisms.Dynamic Neurocognitive Adaptation is a new scale to assess lifetime protective factors.Dynamic Neurocognitive Adaptation is a reliable, novel, and easy to complete scale.This approach can characterize specific life stages that are ripe for risk-reduction interventions.Our scale can be used to personalize health recommendations in aging.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

衰老中的动态神经认知适应：新量表的开发和验证。

导语：45%的阿尔茨海默病（AD）病例可以通过保护因素来预防。储备、恢复力和抵抗具有共同的神经认知适应过程，通过保护机制起作用。在这篇文章中，我们提出了一个新的尺度的发展和验证，称为动态神经认知适应，在这个方向上发展。方法：我们纳入815名参与者(50%为女性；65岁以上（含年龄），分为两个子样本进行探索性和验证性因素分析。我们最初的量表由30个项目组成，调查了7个维度，通过5点李克特量表反映了7个时间窗口的活动频率。结果：我们的最终量表有20个项目，分为四个维度：身体、认知、创造力和社交。不存在多重共线性或非共线性的问题。Kaiser-Meyer-Olkin (KMO) = 0.80， Bartlett球度检验结果均≤0.01；Cronbach’s alpha = 0.83。讨论：我们验证了一种可靠、新颖、易于完成、全面的终身行为评估量表，可用于阿尔茨海默病风险降低、轻度认知障碍的研究和临床实践。重点：储备、抵抗和恢复具有相似的适应机制。动态神经认知适应是一种评价终身保护因素的新量表。动态神经认知适应量表是一种可靠、新颖、易于完成的量表。这种方法可以描述适合采取降低风险干预措施的特定生命阶段。我们的量表可以用来为老年人提供个性化的健康建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.